Jubilant Pharmova Limited (IN:JUBLPHARMA)
:JUBLPHARMA
Want to see IN:JUBLPHARMA full AI Analyst Report?
JUBLPHARMA Stock Chart & Stats
₹1056.10
₹15.25(1.49%)
At close: 4:00 PM EST
₹1056.10
₹15.25(1.49%)
Day’s Range― - ―
52-Week Range₹783.75 - ₹1,250.00
Previous CloseN/A
Volume282.20K
Average Volume (3M)7.42K
Market Cap
₹147.61B
Enterprise Value₹169.40B
Total Cash (Recent Filing)₹6.23B
Total Debt (Recent Filing)₹28.83B
Price to Earnings (P/E)76.0
Beta1.04
Next Earnings
May 29, 2026EPS Estimate
7.45Next Dividend Ex-DateN/A
Dividend Yield0.46%
Share Statistics
EPS (TTM)5.00
Shares Outstanding159,281,140
10 Day Avg. Volume4,911
30 Day Avg. Volume7,424
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.33
Price to Sales (P/S)2.01
P/FCF Ratio-334.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,310.00Price Target Upside24.04% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)45.25
Revenue Forecast (FY)₹91.26B
Bulls Say, Bears Say
Bulls Say
Diversified Business ModelJubilant Pharmova's multi‑pillar model (specialty finished drugs, CDMO services, APIs and radiopharma/discovery) provides structural revenue diversification. This reduces single‑market cyclicality, supports cross‑selling, and sustains demand and utilization over quarters as contract and product revenues offset each other.
Revenue And Margin ImprovementReported improvement in gross and EBIT margins alongside near‑9% revenue growth indicates operational efficiencies and pricing/product mix gains. Sustained margin expansion enhances ability to fund R&D and capacity, and supports medium‑term profitability even if top‑line growth moderates.
Manageable Leverage And Strong Equity BaseA modest debt-to-equity and roughly 49% equity ratio point to a conservative balance sheet that preserves financial flexibility for contract wins or capex. Improved ROE near 13.4% shows capital is generating returns, supporting durable funding capacity for growth or cyclical downturns.
Bears Say
Negative Free Cash FlowDespite solid operating cash generation, heavy capital expenditures produced negative free cash flow and an unfavorable FCF-to-net‑income ratio. Persistent negative FCF can constrain reinvestment, debt reduction, and shareholder returns unless capex normalizes or operating cash improves materially.
Relatively Low Net Profit MarginA net margin around 11.6% limits the portion of revenue that converts to retained earnings and cash, leaving less buffer for cost shocks or pricing pressure in generics and contract businesses. Even with gross/EBIT gains, modest net margins reduce long‑term cash available for strategic investments.
Earnings Per Share DeclineA material decline in EPS signals underlying profit or dilution pressures that could persist absent operational fixes. Falling EPS over multiple quarters can restrict capital raising options, harm investor confidence, and indicate that margin or one‑time costs are eroding durable shareholder returns.
Jubilant Pharmova Limited News
JUBLPHARMA FAQ
What was Jubilant Pharmova Limited’s price range in the past 12 months?
Jubilant Pharmova Limited lowest stock price was ₹783.75 and its highest was ₹1250.00 in the past 12 months.
What is Jubilant Pharmova Limited’s market cap?
Jubilant Pharmova Limited’s market cap is ₹147.61B.
When is Jubilant Pharmova Limited’s upcoming earnings report date?
Jubilant Pharmova Limited’s upcoming earnings report date is May 29, 2026 which is in 25 days.
How were Jubilant Pharmova Limited’s earnings last quarter?
Jubilant Pharmova Limited released its earnings results on Feb 06, 2026. The company reported ₹5 earnings per share for the quarter, missing the consensus estimate of ₹8.25 by -₹3.25.
Is Jubilant Pharmova Limited overvalued?
According to Wall Street analysts Jubilant Pharmova Limited’s price is currently Undervalued.
Does Jubilant Pharmova Limited pay dividends?
Jubilant Pharmova Limited pays a Annually dividend of ₹5 which represents an annual dividend yield of 0.46%. See more information on Jubilant Pharmova Limited dividends here
What is Jubilant Pharmova Limited’s EPS estimate?
Jubilant Pharmova Limited’s EPS estimate is 7.45.
How many shares outstanding does Jubilant Pharmova Limited have?
Jubilant Pharmova Limited has 159,281,140 shares outstanding.
What happened to Jubilant Pharmova Limited’s price movement after its last earnings report?
Jubilant Pharmova Limited reported an EPS of ₹5 in its last earnings report, missing expectations of ₹8.25. Following the earnings report the stock price went down -4.177%.
Which hedge fund is a major shareholder of Jubilant Pharmova Limited?
Currently, no hedge funds are holding shares in IN:JUBLPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jubilant Pharmova Limited
Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages in the manufacturing and supply of allergy therapy products, contract manufacturing of sterile injectables and non-sterile products, active pharmaceutical ingredients, and solid dosage formulations, as well as sale of radiopharmaceuticals through a network of 48 radio pharmacies in the United States. The Contract Research & Development Services segment provides collaborative research services to pharmaceutical innovators. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune disorders. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is headquartered in Noida, India.
JUBLPHARMA Stock 12 Month Forecast
Average Price Target
₹1,310.00
▲(24.04% Upside)
Technical Analysis
Glenmark Life Sciences Limited
―
Granules India Limited
―
Neuland Laboratories Ltd.
―
Strides Pharma Science Ltd
―
Wockhardt Limited
―